Home Business Humacyte Announces Successful Closing of Business

Humacyte Announces Successful Closing of Business

  • Humacyte raises $245M gross proceeds
  • Combined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021
  • Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial disease
  • Combined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive team
  • Kathleen Sebelius appointed Chair of the Board of Directors
  • Humacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021

DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the successful completion of its business combination (the “Business Combination”) with Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC)…

Click here for full article…www.globenewswire.com